Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Condition: Oropharyngeal Squamous Cell Carcinoma (SCC) Interventions: Biological: PRGN-2009; Drug: Pembrolizumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Oropharyngeal Cancer | Research | Vaccines